Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue
See the article here:
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
Company to Host International Roadshow the Week of January 13, 2025
Link:
Renovaro Issues Shareholder Letter and Provides Corporate Update
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET.
Original post:
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives
Read the rest here:
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
MINNEAPOLIS, MN, Jan. 07, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold a special meeting of its shareholders at 10.30am EST on Friday, January 17, 2025.
Visit link:
FOXO TECHNOLOGIES INC.’S BOARD OF DIRECTORS ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS
Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on January 6, 2025 (the “Meeting”), as set out in the Company’s Management Information Circular dated December 1, 2024, were approved by the requisite majority of votes cast at the Meeting, including a resolution fixing the board of directors at five members, the election of directors of the Company for the ensuing year, to appoint Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network, as auditor of the Company, a resolution to establish and approve an omnibus equity incentive plan and a resolution allowing the directors, if they deem such an action to be in the best interest of shareholders, effect a consolidation (the “Consolidation”) of the common shares in the capital of the Company (the “Shares”) on the basis of fifty (50) pre-Consolidation Shares for one (1) post-Consolidation Share, or such other lesser consolidation ratio as determined by the Company’s board of directors.
See the rest here:
Clearmind Medicine Announces Shareholders Meeting Results
LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced successful completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an investigational CAR-T therapy, in patients relapsed/refractory (R/R) AL Amyloidosis. Achievement of this milestone is expected to accelerate enrollment across U.S. study sites beginning in January 2025.
Continued here:
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
IRVINE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering closed on January 7, 2025.
Go here to see the original:
AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Continued here:
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that Michel Dahan, President and Chief Executive Officer, will provide a corporate update and present the latest clinical study results for the company’s investigational oral therapy to prevent blindness in patients with Stargardt disease, during the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Read the original:
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference